“…Some but not all previous studies have suggested an association between clinical phenotype, frequency of exacerbations or severity of disability, and the detection of autoantibodies. [4], [8], [12], [14], [15] It is possible that potential inclusion of NMO/NMOSD patients may have influenced these results. Our data is in agreement with studies [3]–[4], [6]–[7], [9], [10], [13], [22], [24] that have identified no association with clinical severity.…”